Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA4 | P22748 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SLC18A3 | Q16572 | 3/20 | 0.34 |
| ▸ | GBA1 | P04062 | 4/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17201940 | 0.97 | EPHX1 (0.42) | EPHX1CA1CA2CA4LMNA | |
| 1,4-Butanediol SCHEMBL28231182 | 0.97 | CA1 (0.41) | EPHX1CA1CA2CA4LMNA | |
| 1,5-Pentanediol SCHEMBL2844810 | 0.94 | LMNA (0.36) | EPHX1CA1CA2CA4LMNA | |
| 1,3-Propanediol SCHEMBL6379474 | 0.91 | CA1 (0.41) | EPHX1CA1CA2CA4TSHR | |
| 1,4-Butanediol SCHEMBL3681996 | 0.84 | SMN1; SMN2 (0.37) | EPHX1LMNATSHRALDH1A1HSD17B10 | |
| Ethylene Glycol SCHEMBL11128853 | 0.81 | CA1 (0.43) | CA1CA2CA4TSHRSLC18A3 | |
| Butyl Alcohol SCHEMBL27528881 | 0.81 | ALDH1A1 (0.55) | CA1CA2CA4LMNATSHR | |
| SCHEMBL28291025 | 0.81 | CA1 (0.47) | CA1CA2CA4TSHRALDH1A1 | |
| SCHEMBL30119591 | 0.79 | CA1 (0.52) | EPHX1CA1CA2CA4SLC18A3 | |
| SCHEMBL812021 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114058198-B | Composition for packaging OLED, packaging film layer and OLED display | 武汉柔显科技股份有限公司 | 2022-04-22 | — | — | CN | disclosed |
| CN-114058198-A | Composition for packaging OLED, packaging film layer and OLED display | 武汉柔显科技股份有限公司 | 2022-02-18 | — | — | CN | disclosed |
| US-20120214749-A1 | MICROPARTICLES COMPRISING SOMATOSTATIN ANALOGUES | NOVARTIS AG (CH) | 2012-08-23 | — | — | US | disclosed |
| US-8188037-B2 | Microparticles comprising somatostatin analogues | NOVARTIS AG (CH) | 2012-05-29 | — | — | US | disclosed |
| US-20110034418-A1 | PHARMACEUTICAL COMPOSITION WITH BISPHOSPHONATE | NOVARTIS AG (CH) | 2011-02-10 | — | — | US | disclosed |
| US-20100272809-A1 | MICROPARTICLES COMPRISING SOMATOSTATIN ANALOGUES | RECORDATI AG (CH) | 2010-10-28 | — | — | US | disclosed |
| EP-1686964-B9 | MICROPARTICLES COMPRISING SOMATOSTATIN ANALOGUES | NOVARTIS AG (CH) | 2010-08-04 | — | — | EP | disclosed |
| US-7759308-B2 | Microparticles comprising somatostatin analogues | NOVARTIS AG (CH) | 2010-07-20 | — | — | US | disclosed |
| US-20100047306-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING BISPHOSPONATES | NOVARTIS AG (CH) | 2010-02-25 | — | — | US | disclosed |
| EP-1686964-B1 | MICROPARTICLES COMPRISING SOMATOSTATIN ANALOGUES | NOVARTIS AG (CH) | 2010-01-20 | — | — | EP | disclosed |
| US-20070212418-A1 | Microparticles comprising somatostatin analogues | RECORDATI AG (CH) | 2007-09-13 | — | — | US | disclosed |
| US-5245003-A | Polyesters | EASTMAN KODAK COMPANY (US) | 1993-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214749-A1 | MICROPARTICLES COMPRISING SOMATOSTATIN ANALOGUES | SSTR5, SSTR3, SSTR4 | EPHX1 4048/4885CA1 1310/4885CA2 2702/4885 |
| US-20100047306-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING BISPHOSPONATES | PTEN, PPIP5K2, ACP3 | EPHX1 2494/4885CA1 2846/4885CA2 1081/4885 |
| US-20110034418-A1 | PHARMACEUTICAL COMPOSITION WITH BISPHOSPHONATE | SOST, SLC20A1, SLC34A1 | EPHX1 3423/4885CA1 2769/4885CA2 941/4885 |
| US-20100272809-A1 | MICROPARTICLES COMPRISING SOMATOSTATIN ANALOGUES | SSTR5, SSTR3, SSTR4 | EPHX1 4048/4885CA1 1310/4885CA2 2702/4885 |
| US-20070212418-A1 | Microparticles comprising somatostatin analogues | SSTR5, SSTR3, SSTR4 | EPHX1 4048/4885CA1 1310/4885CA2 2702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.